EFFECTIVE Act

HR 1375, the EFFECTIVE Act, requires the FDA to deny approval for new opioid pain medications unless they demonstrate a significant safety or effectiveness advantage over existing opioid drugs. This directly affects pharmaceutical companies developing new opioid analgesics by raising the approval standard. The bill amends the Federal Food, Drug, and Cosmetic Act to mandate that the FDA Secretary must determine if a new opioid offers meaningful benefits before granting approval. It does not change approval for non-opioid drugs or existing opioid medications.